Panion & Bf Biotech Inc. (1760.TW)
TWD 68.7
(-2.41%)
TWD 68.7
(-2.41%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.88 Billion TWD | -21.54% |
| 2022 | 2.39 Billion TWD | 26.16% |
| 2021 | 1.9 Billion TWD | 21.2% |
| 2020 | 1.56 Billion TWD | -0.34% |
| 2019 | 1.57 Billion TWD | 11.73% |
| 2018 | 1.4 Billion TWD | 16.19% |
| 2017 | 1.21 Billion TWD | 15.56% |
| 2016 | 1.04 Billion TWD | -12.93% |
| 2015 | 1.2 Billion TWD | 18.8% |
| 2014 | 1.01 Billion TWD | 18.36% |
| 2013 | 857.08 Million TWD | 26.99% |
| 2012 | 674.89 Million TWD | 15.52% |
| 2011 | 584.24 Million TWD | 11.33% |
| 2010 | 524.77 Million TWD | -6.19% |
| 2009 | 559.39 Million TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 496.58 Million TWD | -0.58% |
| 2024 Q1 | 499.48 Million TWD | -5.52% |
| 2023 Q4 | 528.66 Million TWD | 11.39% |
| 2023 FY | 1.88 Billion TWD | -21.54% |
| 2023 Q1 | 408.52 Million TWD | -12.66% |
| 2023 Q2 | 470.07 Million TWD | 15.06% |
| 2023 Q3 | 474.6 Million TWD | 0.96% |
| 2022 Q1 | 454.56 Million TWD | -2.16% |
| 2022 Q3 | 661.56 Million TWD | -18.81% |
| 2022 Q4 | 467.72 Million TWD | -29.3% |
| 2022 FY | 2.39 Billion TWD | 26.16% |
| 2022 Q2 | 814.79 Million TWD | 79.25% |
| 2021 Q3 | 529.36 Million TWD | -0.72% |
| 2021 Q4 | 464.58 Million TWD | -12.24% |
| 2021 FY | 1.9 Billion TWD | 21.2% |
| 2021 Q1 | 374.04 Million TWD | -27.11% |
| 2021 Q2 | 533.2 Million TWD | 42.55% |
| 2020 Q4 | 513.18 Million TWD | 32.9% |
| 2020 Q1 | 340.6 Million TWD | -26.91% |
| 2020 Q3 | 386.13 Million TWD | 17.47% |
| 2020 FY | 1.56 Billion TWD | -0.34% |
| 2020 Q2 | 328.71 Million TWD | -3.49% |
| 2019 FY | 1.57 Billion TWD | 11.73% |
| 2019 Q4 | 465.98 Million TWD | 33.23% |
| 2019 Q1 | 356.9 Million TWD | -23.32% |
| 2019 Q3 | 349.76 Million TWD | -12.84% |
| 2019 Q2 | 401.29 Million TWD | 12.44% |
| 2018 Q1 | 262.75 Million TWD | -24.02% |
| 2018 FY | 1.4 Billion TWD | 16.19% |
| 2018 Q4 | 465.43 Million TWD | 40.43% |
| 2018 Q3 | 331.44 Million TWD | -5.06% |
| 2018 Q2 | 349.11 Million TWD | 32.87% |
| 2017 Q1 | 282.01 Million TWD | -16.83% |
| 2017 Q2 | 270.15 Million TWD | -4.2% |
| 2017 Q3 | 314.48 Million TWD | 16.41% |
| 2017 FY | 1.21 Billion TWD | 15.56% |
| 2017 Q4 | 345.81 Million TWD | 9.96% |
| 2016 Q2 | 230.86 Million TWD | 0.0% |
| 2016 Q4 | 339.09 Million TWD | 36.5% |
| 2016 Q3 | 248.42 Million TWD | 7.61% |
| 2016 FY | 1.04 Billion TWD | -12.93% |
| 2016 Q1 | 230.86 Million TWD | -27.72% |
| 2015 FY | 1.2 Billion TWD | 18.8% |
| 2015 Q4 | 319.4 Million TWD | 0.0% |
| 2015 Q3 | 319.4 Million TWD | 12.81% |
| 2015 Q2 | 283.12 Million TWD | 0.0% |
| 2015 Q1 | 283.12 Million TWD | -0.16% |
| 2014 Q2 | 223.61 Million TWD | 0.0% |
| 2014 FY | 1.01 Billion TWD | 18.36% |
| 2014 Q1 | 223.61 Million TWD | -7.83% |
| 2014 Q4 | 283.58 Million TWD | 0.0% |
| 2014 Q3 | 283.58 Million TWD | 26.82% |
| 2013 Q3 | 242.61 Million TWD | 30.49% |
| 2013 Q4 | 242.61 Million TWD | 0.0% |
| 2013 FY | 857.08 Million TWD | 26.99% |
| 2013 Q1 | 185.92 Million TWD | 0.29% |
| 2013 Q2 | 185.92 Million TWD | 0.0% |
| 2012 FY | 674.89 Million TWD | 15.52% |
| 2012 Q3 | 185.38 Million TWD | 0.0% |
| 2012 Q4 | 185.38 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | 584.24 Million TWD | 11.33% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | 524.77 Million TWD | -6.19% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 559.39 Million TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Apex Biotechnology Corp. | 1.67 Billion TWD | -12.248% |
| Sinphar Pharmaceutical Co.,Ltd. | 2.96 Billion TWD | 36.486% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 2.08 Billion TWD | 9.805% |
| GenMont Biotech Incorporation | 318.01 Million TWD | -491.757% |
| Abnova (Taiwan) Corporation | 382.05 Million TWD | -392.57% |
| Adimmune Corporation | 1.78 Billion TWD | -5.422% |
| Tanvex BioPharma, Inc. | 61.41 Million TWD | -2964.394% |
| Polaris Group | 7.48 Million TWD | -25055.394% |
| Energenesis Biomedical CO.,LTD. | 7.15 Million TWD | -26190.514% |
| UnicoCell Biomed Co., Ltd. | 24.58 Million TWD | -7553.321% |
| PELL Bio-Med Technology Co. Ltd. | 18.03 Million TWD | -10335.729% |